Immunic (IMUX) Set to Announce Quarterly Earnings on Thursday

Immunic (NASDAQ:IMUX - Get Free Report) will be posting its quarterly earnings results before the market opens on Thursday, November 7th. Analysts expect Immunic to post earnings of ($0.22) per share for the quarter. Parties interested in registering for the company's conference call can do so using this link.

Immunic (NASDAQ:IMUX - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.02. During the same period in the prior year, the company posted ($0.54) EPS. On average, analysts expect Immunic to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immunic Stock Performance

Shares of NASDAQ IMUX traded down $0.02 during trading on Friday, reaching $1.19. The stock had a trading volume of 618,031 shares, compared to its average volume of 598,536. The stock has a market cap of $107.20 million, a PE ratio of -0.79 and a beta of 1.84. The firm's 50 day moving average price is $1.49 and its two-hundred day moving average price is $1.35. Immunic has a one year low of $0.95 and a one year high of $2.11.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. EF Hutton Acquisition Co. I upgraded shares of Immunic to a "strong-buy" rating in a report on Monday, September 16th. Piper Sandler reissued an "overweight" rating and issued a $28.00 price objective on shares of Immunic in a research note on Tuesday, July 16th. Leerink Partners reaffirmed an "outperform" rating and set a $5.00 target price on shares of Immunic in a research note on Monday, September 9th. Leerink Partnrs upgraded shares of Immunic to a "strong-buy" rating in a research report on Monday, September 9th. Finally, StockNews.com raised shares of Immunic from a "sell" rating to a "hold" rating in a report on Tuesday, August 13th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $11.20.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.